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The high incidence of insulin resistance and the metabolic syndrome in South Asians remains unexplained. I
propose that a defect in the activity of Δ
6 and Δ
5 desaturases and consequent low plasma and tissue concentra-
tions of polyunsaturated fatty acids such as g-linolenic acid (GLA), dihomo-g-linolenic acid (DGLA), arachidonic acid
(AA), eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) and formation of their anti-inflammatory
products prostaglandin E1 (PGE1), prostacyclin (PGI2), PGI3, lipoxins, resolvins, protectins, maresins and nitrolipids
could be responsible for the high incidence of insulin resistance, the metabolic syndrome and ischemic heart dis-
ease (IHD) in South Asians. This proposal is supported by the observation that South Asian Indians have lower
plasma and tissue concentrations of GLA, DGLA, AA, EPA and DHA, the precursors of PGE1, PGI2, PGI3, lipoxins,
resolvins, protectins, and nitrolipids, the endogenous molecules that prevent platelet aggregation, vasoconstriction,
thrombus formation, leukocyte activation and possess anti-inflammatory action and thus, are capable of preventing
the development of insulin resistance, atherosclerosis, hypertension, type 2 diabetes mellitus and premature
ischemic heart disease. Genetic predisposition, high carbohydrate intake, lack of exercise, tobacco use and low
birth weight due to maternal malnutrition suppress the activity of Δ
6 and Δ
5 desaturases that leads to low plasma
and tissue concentrations of polyunsaturated fatty acids and their products. This implies that adequate provision of
polyunsaturated fatty acids and co-factors needed for their metabolism, and efforts to enhance the formation of
their beneficial metabolites PGE1, PGI2, PGI3, lipoxins, resolvins, protectins, maresins and nitrolipids could form a
novel approach in the prevention and management of these diseases in this high-risk population.
Introduction
T h eh i g hp r e v a l e n c eo fi s c h e m i ch e a r td i s e a s ei nS o u t h
Asians has been attributed to abdominal obesity,
tobacco use, dyslipidemia, hypertension, diabetes melli-
tus, abdominal obesity and lack of exercise [1]. All these
factors are known to be associated with insulin resis-
tance that could account for the high incidence of
ischemic heart disease in South Asians [2]. Almost 60%
of the world’s heart disease is expected to occur in
South Asians. Hence, it is essential that pathophysiology
of the disease as to why it is common in South Asians
needs to be understood to develop relevant preventive
and therapeutic strategies.
In a study that evaluated the differences in postpran-
dial glycemia and insulin sensitivity among young adults
of different ethnic origins, it was noted that young
South East Asians had the highest postprandial glycemia
and lowest insulin sensitivity, whereas European and
Arabic Caucasian subjects were the most insulin sensi-
tive and carbohydrate tolerant. These findings suggest
that insulin resistance is evident even in lean, young
adults of South Asian origin even when they are healthy
[3]. In addition, ethnicity appears to be an important
risk factor for type 2 diabetes in dysglycaemic persons.
In a 2-by-2 factorial double-blind randomized controlled
trial that compared the effects of rosiglitazone and
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persons meeting criteria for impaired glucose tolerance
or impaired fasting glucose, it was noted that South
Asians experienced a smaller, and Latinos a larger pre-
ventive effect [4], suggesting that South Asians respond
less favorably to the preventive effects of rosiglitazone.
But, none of these studies could pinpoint the underlying
cause for the higher incidence of insulin resistance in
South Asians.
Polyunsaturated fatty acids enhance cell
membrane fluidity and decrease Insulin resistance
Insulin resistance is common in obesity, type 2 diabetes
mellitus, essential hypertension, hyperlipidemia,
ischemic (coronary) heart disease, atherosclerosis, age-
ing, polycystic ovarian disease and the metabolic syn-
drome. Increased consumption of energy dense food
induces insulin resistance, leads to the development of
obesity, the precursor of the metabolic syndrome. Cal-
orie restriction, reduced food intake, increase in energy
expenditure in the form of exercise attenuates insulin
resistance, decreases the incidence of obesity, type 2 dia-
betes mellitus, hypertension and the metabolic
syndrome.
Insulin has to bind to its receptors on the cell mem-
brane to bring about its actions. Hence, cell membrane
structure and its functional integrity influence the prop-
erties of the insulin receptor including its affinity to
insulin. The properties of cell membrane especially, its
fluidity depend on the lipid constitution of the mem-
brane. High saturated fatty acid(s) content of the mem-
brane will render it more rigid (i.e. decrease in fluidity)
that leads to a decrease in the number of insulin recep-
tors and the affinity of insulin to its receptors [5-11].
This, in turn, causes insulin resistance and associated
hyperinsulinemia. It was reported that an increase in the
amount of polyunsaturated fatty acids in the cell mem-
brane may produce a significant increase of the number
of high-affinity sites with a concomitant decrease of
low-affinity sites for insulin [9,11].
These in vitro results are supported by in vivo experi-
ments wherein it was observed that feeding animals
with diets high in saturated fat induced insulin resis-
tance, and replacing saturated fat isocalorically with
polyunsaturated fat, especially long-chain ω-3 fatty
acids, prevented the development of insulin resistance in
skeletal-muscle tissue. The content of fatty acids in sar-
colemmal phospholipid was significantly related to the
dietary composition. Insulin binding to intact sarcolem-
mal vesicles prepared from rats fed on diets high in ω-3
fatty acids increased 14-fold compared with animals fed
on the low-ω-3 diet and the former showed increased
sarcolemmal insulin binding by 2.3-fold. Increased insu-
lin binding was due to increased receptor number at the
low-affinity high-capacity binding site, suggesting that
dietary ω-3 and polyunsaturated fatty acids increase
insulin binding to sarcolemma by changing the fatty
acyl composition of phospholipid surrounding the insu-
lin receptor, an action by which dietary fatty acids seem
to modify insulin action [12].
In addition, diet rich in fish oil, a rich source of EPA
and DHA, prevented obesity, hyperlipidemia and adipo-
cyte insulin resistance in rats [13,14] lending support to
this view.
Mechanisms of anti-atherosclerotic actions of
PUFAs
Although the exact mechanism by which PUFAs/EFAs
decrease insulin resistance is not known, some of the
possibilities include: (a) increase in the number of insu-
lin receptors due to increased membrane fluidity; (b) an
increase in GLUT-4 mRNA and protein level in adipo-
cytes [15]; (c) formation of anti-inflammatory and anti-
atherosclerotic molecules such as PGI2,P G E 1, lipoxins,
resolvins, protectins and maresins [16-21]; (d) suppres-
sion of the expression of adhesion molecules [22-24]; (e)
inhibition of the formation of pro-inflammatory cyto-
kines tumor necrosis factor-a (TNF-a), macrophage
migration factor (MIF), high-mobility group box 1
(HMGB1) and interleukin-6 (IL-6) [25-27]; (f) enhance-
ment in the formation of brain-derived neurotrophic
factor (BDNF) in the brain and gut that has anti-diabetic
actions [28-30]; and that (BDNF), in turn, augments
PGI2 synthesis [31], a potent platelet anti-aggregator,
vasodilator and anti-atherosclerotic molecule; (f)
enhancement in the synthesis and action of BMPs (bone
morphogenetic proteins) that enhance the growth and
development of the brain [32,33]; (g) modulation of the
growth and actions of gut bacteria [34-37]; (h) binding
to various nuclear receptors and correction of dyslipide-
mia [38-42]; and (i) regulation of both the secretion and
actions of various hypothalamic neurotransmitters and
peptides that regulate appetite, satiety, food intake and
insulin secretion [43-49]. Furthermore, insulin enhances
the activity of Δ
6 and Δ
5 desaturases [50] and thus,
potentially augments the formation of PUFAs that, in
turn, enhance the action of insulin. It is likely that when
the intake of PUFAs is adequate (it should be adequate
throughout life, especially during the formative periods
of various cells and tissues and programming of their
functions and responses to various endogenous and exo-
genous stimuli and stresses including perinatal period),
the incorporation of these fatty acids into the cell mem-
brane of endothelial cells will be optimum such that the
production of PGI2, PGE1, lipoxins, resolvins, protectins,
maresins and nitrolipids will be sufficient both during
health and in instances of exposure to adverse stimuli
such as shear stress so that the expression of adhesion
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kines will be suppressed to prevent platelet aggregation
and initiation and progression of atherosclerosis. Thus,
for the maintenance of optimal health of endothelial
cells adequate intake of PUFAs though out life both
during the perinatal period and adult life is necessary. In
the absence of adequate amounts of PUFAs, endothelial
cells will not be able to synthesize and release sufficient
quantities of PGE1,P G I 2,P G I 3, lipoxins, resolvins, pro-
tectins, maresins and nitrolipids that could lead to
endothelial dysfunction, insulin resistance and finally the
initiation and progression of the metabolic syndrome
and ischemic heart disease.
South Asians are deficient in beneficial PUFAs
If this proposal is true, it implies that South Asians are
deficient in PUFAs. Previously, I showed that even
healthy Indians have lower concentrations of various
PUFAs compared to Canadians and Americans (USA)
[51], suggesting that Indians have low activity of Δ
6
and Δ
5 desaturases (see Figure 1 for metabolism of
essential fatty acids). This, in turn, could lead to
decreased formation of PGE1,P G I 2,P G I 3,l i p o x i n s ,
resolvins, protectins, maresins and nitrolipids due to
precursor PUFA deficiency. This is further supported
by the observation that South Asians with IHD have
much lower levels of PUFAs in their plasma phospholi-
pid fraction compared to healthy subjects [52].
Furthermore, low activity of Δ
6 and Δ
5 desaturases
could lead to the initiation and progression of insulin
resistance and atherosclerosis [53,54]. These evidences
suggest that South Asians are at high risk of develop-
ing type 2 diabetes mellitus, the metabolic syndrome,
IHD and its associated death and complications due to
a defect in the activity of Δ
6 and Δ
5 desaturases that
result in low plasma and tissue concentrations of
PUFAs and their products: PGE1,P G I 2,P G I 3, lipoxins,
resolvins, protectins, maresins and nitrolipids that are
necessary to prevent platelet aggregation, lower blood
p r e s s u r e ,r e d u c eL D L - C ,a m e liorate the adverse actions
of homocysteine, and inhibit ACE (angiotensin con-
verting enzyme) and HMG-CoA enzyme activities
[20,55]. In addition, PUFAs and their beneficial pro-
d u c t ss u c ha sP G I 2 and lipoxins have anti-arrhythmic
action, enhance wound healing and suppress inflamma-
tion [19-21,56-58].
Folic acid that reduces plasma homocysteine levels
augments the metabolism of essential fatty acids such
that plasma and tissue levels of various PUFAs are
enhanced [59,60]. Similar potentiating action of vitamin
B6 on Δ
6 and Δ
5 desaturases was also reported [59-62].
Recently it was noted that the gene that encodes the 5-
lipoxygenase activating protein (FLAP) and its risk var-
iant results in an almost 2-fold increased risk of IHD by
leading to the production of leukotriene B4 (LTB4), a
potent chemokine mediators of arterial inflammation
[63,64]. This is supported by the observation that
patients with IHD produce more LTB4 than controls,
suggesting that LTB pathway is upregulated in IHD. It
is interesting to note that lipoxins are potent inhibitors
of LTB4 and leukotrienes [65,66].
These evidences suggest that South Asians are at high
risk to develop insulin resistance, type 2 diabetes melli-
tus, the metabolic syndrome and IHD due to low levels
o fv a r i o u sP U F A s ,L X s ,r e s o l v i n s ,p r o t e c t i n s ,m a r e s i n s
and nitrolipids, and hence could benefit from supple-
mentation of PUFAs. Furthermore, South Asians con-
sume less amounts of ω-3 PUFAs and more of saturated
and trans-fats that are known to inhibit the activity of
Δ
6 and Δ
5 desaturases [6,7,16-18] which, in turn, further
aggravate their tendency to develop insulin resistance
and the metabolic syndrome [67]. Since, South Asians
have low plasma levels of various PUFAs and consume
significantly lower quantities of ω-3 PUFAs; they are
more prone to have low-grade systemic inflammation.
This is supported by the observation that of 1250 adults
of South Asian, Chinese, European and Aboriginal
ancestry studied; the age- and sex-adjusted mean CRP
was 3.74 ± 0.14 mg/L among Aboriginals, 2.59 mg/L ±
0.12 among South Asians, and 1.18 ± 0.13 mg/L among
Chinese compared with 2.06 ± 0.12 mg/L among Eur-
opeans (overall P < 0.0001). Differences in the CRP con-
centration between ethnic groups were substantially
diminished, but not abolished, after adjustment for
metabolic factors. CRP was independently associated
with CVD (cardiovascular diseases) after adjusting for
the Framingham risk factors, atherosclerosis, anthropo-
metric measurements, and ethnicity (OR = 1.03 for a
0.1-increase in CRP; P = 0.02). These results clearly
indicate that South Asians are more prone to have low-
grade systemic inflammation compared to other ethnic
groups [68] that may render them highly susceptible to
cardiovascular diseases.
Leukocyte activation and atherosclerosis
One of the major health issues in South Asians is the
occurrence of premature atheroslcerosis and consequent
IHD that, in turn, is due to insulin resistance. Leuko-
cytes seem to play a major role in the pathobiology of
atherosclerosis. Thus, peripheral leukocytes could be
used as a marker of insulin resistance and atheroslcero-
sis by studying the metabolism of essential fatty acids,
eicosanoids, lipoxins, resolvins, protectins, maresins,
nitrolipids and nitric oxide in these cells. Since leukocy-
tosis is also a marker of inflammation, study of leuko-
cytes and their functions could reflect the underlying
pathobiology of low-grade systemic inflammation and its
consequences. For instance, higher leukocyte count is
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implies that leukocyte myeloperoxidase (MPO) could
serve as a biomarker of cardiovascular diseases as
reported by Morrow et al [70].
Infiltration of intima by leukocytes and macrophages
is an early event to occur in atherosclerosis, suggesting
that leukocyte activation is an early event in athero-
sclerosis. Since atherosclerotic lesions occur in a patchy
Figure 1 Metabolism of essential fatty acids (EFAs). Red arrows indicate inhibition of activity of Δ
6 and Δ
5 desaturases while green arrows
indicate enhancement of their activity. It is predicted that under normal oxidative conditions adequate formation of PGE1, PGI2, PGI3, lipoxins,
resolvins, protectins, maresins and nitrolipids will occur that would prevent low-grade systemic inflammation and insulin resistance. Isoprostanes
and neuroprostanes are also formed from PUFAs under certain specific circumstances that have anti-inflammatory and neuroprotective
properties. On the other hand, under conditions of excess oxidative stress not only the formation of PGE1, PGI2, PGI3, lipoxins, resolvins,
protectins, maresins, nitrolipids and endothelial nitric oxide is decreased or abrogated but would also lead to the formation of excess of pro-
inflammatory eicosanoids such as PGE2, PGE3, PGF2a, PGF3a, leukotrienes and thromboxanes. PUFAs, various eicosanoids, lipoxins, resolvins,
protectins, maresins, nitrolipids and endothelial nitric oxide may bring about their various actions by acting or modulating nuclear receptors, LXR,
FXR, RAR-RXR, Syntaxin, PPARs, eNO, Ras, GTPases, NF-B, UCPs, G-protein coupled receptors (GPRs),phospholipases, ROS, anti-oxidants, cytokines,
neurotransmitters, growth factors, cytokeratins, various genes, oncogenes and anti-oncogenes.
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branch points, and inner curvatures of arteries, it sug-
gests that local factors play a significant role in the
development of atherosclerosis. Hemodynamic forces
induce the expression of pro-inflammatory genes [71]
that initiate and accelerate atherosclerosis at these
points of shear stress. Normocholesterolemic C57BL/6
mice and rabbits showed activation of NF-B and ele-
vated expression of VCAM-1 and ICAM-1, upregulation
of pro-inflammatory genes IL-1, IL-6, MCP-1, as well as
antioxidant genes glutathione peroxidase and glu-
tathione-S- transferase 2 in endothelial cells in athero-
sclerosis-susceptible regions of the ascending aorta
[53,71]. Intimal accumulation of LDL and its oxidation
products preceded monocyte recruitment into early
atherosclerotic lesions, suggesting that lipid accumula-
tion triggers inflammatory response characterized by
upregulation of the expression of chemokines and adhe-
sion molecules in the lesion-prone areas in the intima
that contributes to leukocyte accumulation and athero-
sclerotic lesion formation [72-75]. Thus at atheroslcero-
sis-prone regions of the normal intima, inflammatory
response is triggered in response to risk factors that up
regulate several proinflammatory genes, which mediate
accumulation of leukocytes and initiation and perpetua-
tion of atherosclerosis.
Healthy endothelial cells have the ability to prevent
excess expression of adhesion molecules, resist increases
in LDL and cholesterol transport and retention, abrogate
activation of NF-B and the induction of expression of
pro-inflammatory genes induced by hemodynamic forces
at atherosclerosis prone regions due to enhanced infil-
tration by monocytes, CD68
+ leukocytes, and macro-
phages by elaborating factors/molecules that counter
pro-atherosclerotic events. The patchy nature of athero-
sclerosis suggests that arterial walls undergo regional
disturbances of metabolism that include the uncoupling
of respiration and oxidative phosphorylation, which may
be characteristic of blood vessels being predisposed to
the development of atherosclerosis [76]. Oxidative stress,
and abnormalities of uncoupling proteins produce
smooth muscle contraction and cause hypertension [77],
and respiratory uncoupling is increased in the aortae of
experimental animals that are susceptible to athero-
sclerosis [76]. Bernal-Mizrachi et al [78] showed that
UCP-1 expression in aortic smooth muscle cells causes
hypertension and increases atherosclerosis without
affecting cholesterol levels. This increase in UCP-1
expression enhanced superoxide anion production and
decreased the availability of nitric oxide (NO), suggest-
ing that oxidative stress has been elevated. Thus, ineffi-
cient metabolism in blood vessels causes atherosclerosis.
One of the earliest signs of atherosclerosis is the
development of abnormal mitochondria in smooth
muscle cells [79]. Arteries have marginal oxygenation
[80] and hypoxia reduces the respiratory control ratio.
Uncoupled respiration precedes atherosclerosis at
lesion-prone sites but not at the sites that are resistant
to atherosclerosis [76]. Disease-free aortae have abun-
dant concentrations of the essential fatty acid (EFA)-
linoleate and possibly anti-inflammatory lipoxins, resol-
vins, protectins, maresins and nitrolipids whereas fatty
streaks are deficient in EFAs [78,81,82]. EFA deficiency
promotes respiratory uncoupling [83,84] and athero-
sclerosis [53,78,85]. Hence, local disturbances of
metabolism in the arterial wall are responsible for ather-
osclerosis and vascular diseases such as IHD.
Aspirin converts arachidonic acid (AA; 20:4 ω-6),
eicosapentaenoic acid (EPA; 20:5 ω-3) and docosahexae-
noic acid (DHA; 22:6 ω- 3 )t of o r ma s p i r i n - t r i g g e r e d1 5
epimer LXs (ATLs) by activated leukocytes that inhibit
acute inflammation (reviewed in 16-18). These 15-epi-
meric LXs prevent local inflammation on the vessel wall
by regulating the motility of PMNs, eosinophils, and
monocytes. LXs deficiency leads to an interaction
between PMN and endothelial cells that result in
endothelial damage, initiation and progression of athero-
sclerosis [86]. LXs, resolvins and protectins inhibited
cytokine generation, leukocyte recruitment, leukocyte
diapedesis, exudate formation, suppress the production
of pro-inflammatory cytokines. Hence, local deficiency
of LXs, resolvins and NPD1 could initiate atheroslcero-
sis. Furthermore, lipoxins suppress production of MPO
from activated leukocytes [87]. Increased generation of
MPO by leukocytes could be an indication of decreased
formation of lipoxins, resolvins, protectins, maresins and
nitrolipids by endothelial cells. This implies that enhan-
cing the formation of endothelial LXs, resolvins, protec-
tins, maresins and nitrolipids may suppress leukocyte
activation and MPO generation and prevent IHD.
In this context, it is interesting to note that elevated
circulating platelet-monocyte complexes correlated sig-
nificantly with elevated aortic carotid-femoral pulse
wave velocity and platelet-monocyte complexes were
higher in subjects with femoral plaques of South Asian
descent and Europeans. Higher numbers of platelet-
monocyte complexes were independently related to ele-
vated levels of C-reactive protein (CRP), higher carotid-
femoral pulse wave velocity, hypertension and smoking
i nam u l t i v a r i a t em o d e l[ 8 8 ] .T h e s er e s u l t ss u g g e s tt h a t
inflammation as evidence by higher CRP and elevated
platelet-monocyte complexes is closely related to the
extent of atherosclerosis and indicates that leukocyte
activation has an import role in the pathogenesis of
a t h e r o s c l e r o s i si nS o u t hA s i a n s .T h i si m p l i e st h a td e f i -
ciency or lack of endogenous molecules such as lipoxins
that inhibit leukocyte activation could initiate athero-
sclerosis [53,86,87].
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It is evident from the preceding discussion that one sig-
nificant factor that could render South Asians highly
susceptible to develop insulin resistance, type 2 diabetes
mellitus, the metabolic syndrome, IHD and athero-
sclerosis could be a defect in the activity of Δ
6 and Δ
5
desaturases and consequent lower plasma and tissue
concentrations of PUFAs such as GLA, DGLA, AA, EPA
and DHA and reduced formation of anti-inflammatory
products PGE1,P G I 2,P G I 3, lipoxins, resolvins, protec-
tins, maresins and nitrolipids that inhibit leukocyte acti-
vation and enhance insulin action. This implies that
bypassing block in the activities of Δ
6 and Δ
5 desa-
turases by supplementing GLA, DGLA, AA, EPA and
DHA and co-factors that are essential for the metabo-
lism of EFAs so that adequate amounts of PUFAs could
be formed endogenously such as low-dose aspirin, folic
acid, vitamin B6,B 2, L-arginine (to decrease asymmetri-
cal dimethyl arginine, ADMA, levels that are increased
in patients with IHD, type 2 diabetes mellitus, the meta-
bolic syndrome and hypertension; ADMA also interferes
with eNO synthesis), vitamin C and Mg
2+ (magnesium is
an essential for the normal activity of Δ
6 and Δ
5 enzymes)
will not only improve the plasma and cell/tissue content
of various PUFAs but also augment production of benefi-
cial PGE1,P G I 2,P G I 3, lipoxins, resolvins, protectins, mare-
sins, nitrolipids and endothelial nitric oxide (eNO) and
thus, prevent and/or improve insulin resistance, hyperten-
sion, type 2 diabetes mellitus, the metabolic syndrome and
IHD [5-7,13,14,16-21,23,24,26,27,53-62,83-87,89-92] (see
Figure 2).
Furthermore, previously I and my colleagues showed
that AA, EPA and DHA protect pancreatic b cells from
chemical-induced cytotoxicity [89-92] and thus preserve
their insulin producing capacity. These results are sup-
ported by the recent study wherein it was shown that
mfat-1 transgenic mice which produce higher amounts
of ω-3 PUFAs than the wild type showed increased insu-
lin secretion stimulated by glucose, amino acids and glu-
cagon-like peptide and when challenged with TNF-a,
IL-6 and g-interferon the transgenic islets completely
resisted cytokine-induced cell death [93]. These results
suggest that certain PUFAs and their products [94,95]
have b cell cytoprotective actions and thus, help in the
preservation of insulin secreting capacity. Similar to
some PGs, lipoxins, resolvins, protectins, maresins and
nitrolipids have been shown to have cytoprotective
properties [96-98]
In view of the critical role of Δ
6 and Δ
5 desaturases in
essential fatty acid metabolism, it is important to study
their genetic polymorphism in South Asians and corre-
lating these findings with the severity of insulin resis-
tance, type 2 diabetes mellitus and atheroslcerosis in the
carotid arteries, peripheral vascular tree, and coronary
arteries. It was reported that there is a close correlation
between polymorphisms of human Δ
6 and Δ
5 desaturase
genes FADS1 FADS2 and fatty acid composition in
serum phospholipids. Eighteen polymorphisms located
in this gene cluster located at chromosome 11q12-
11q13.1, a region repeatedly found to be linked with
atopy and other complex diseases were genotyped in
727 adults [99-101]. Polymorphisms and statistically
reconstructed haplotypes of FADS1 and the upstream
region of FADS2 showed strongest associations with the
level of the direct precursor of inflammatory eicosa-
noids, the ω-6 fatty acid AA, also strong associations
with levels of the ω-6 fatty acids LA, GLA, C20: 2 ω-6,
DGLA, C22: 4 ω-6 and of the ω-3 fatty acids ALA, EPA
and C22:5 ω-3. Such studies of polymorphisms of
human Δ
6 and Δ
5 desaturase genes in South Asians may
give clues to predict and assess the progress of insulin
resistance, atherosclerosis and IHD.
Peripheral leukocytes-platelet mixed cultures could be
supplemented with AA, EPA and DHA and the forma-
tion of lipoxins, resolvins, protectins, maresins, nitroli-
pids and endothelial nitric oxide could be tested in
S o u t hA s i a n st oi d e n t i f yt h o s ew h oa r eu n a b l et of o r m
adequate amounts of these lipid mediators and NO.
Such subjects need supplementation of various PUFAs,
aspirin, glitazones, statins and other co-factors even if
they appear to be apparently normal to prevent the
development of insulin resistance, atherosclerosis and
IHD in future. Retesting such subjects after supplemen-
tation of PUFAs, aspirin, glitazones, statins and co-fac-
tors to see whether formation of lipoxins, resolvins,
protectins, maresins, nitrolipids and eNO has been
enhanced will be necessary to ascertain their response
to the treatment.
Plasma, RBC, leukocyte and platelet content of various
PUFAs, lipoxins, resolvins, protectins, maresins, nitroli-
pids, NO and other eicosanoids such as PGs, LTs, and
TXs (thromboxanes) and activities of Δ
6 and Δ
5 desa-
turases could be measured both before and after treat-
m e n ta n du s e da sm a r k e r st op r e d i c tf u t u r e
development and prognostic markers of insulin resis-
tance, the metabolic syndrome, atherosclerosis and IHD.
Urinary levels of lipoxins, resolvins, protectins, maresins
and nitrolipids and isoprostanes could also be measured
and used as biochemical indices of response to treat-
ment and more so in those with diabetic nephropathy.
Development of small molecules that could specifically
up regulate the activities of Δ
6 and Δ
5 desaturases may
be useful in the prevention and progression of insulin
resistance, the metabolic syndrome, atherosclerosis and
IHD. Statins and glitazones modulate the activities of Δ
6
and Δ
5 desaturases. Hence, development structural ana-
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and Δ
5 desaturases could be attempted. Since Δ
6 and Δ
5
desaturases are present in many tissues, it is anticipated
that drugs that enhance the activities of Δ
6 and Δ
5 desa-
turases are likely to have other beneficial actions such as
in the treatment of hypertension, dyslipidemia, type 2
diabetes mellitus and Alzheimer’s disease. Since PUFAs
are naturally occurring endogenous substances, present
in almost all tissues and are essential components of all
mammalian cells, it is likely that overexpression of Δ
6
and Δ
5 desaturases is unlikely to have any significant
side effects. This is evident from the fact that Eskimos
consume large amounts of marine fish that are rich in
ω-3 fatty acids EPA and DHA and are not known to
suffer from any significant side effects. Similarly, when
PUFAs have been administered to different types of
patients for long periods of time (from few months to
f e wy e a r s )i tw a sn o t e dt h a tt h e r ew e r en o ta n y
Figure 2 Scheme showing the consequences of a defect in the activity of enzymes Δ
6 and Δ
5 desaturases and their relationship to the
development of low-grade systemic inflammation and insulin resistance, type 2 diabetes mellitus, the metabolic syndrome,
hypertension, atherosclerosis and IHD. Supplementation of various PUFAs, and the co-factors that arenecessary for the adequate formation of
PGE1, PGI2, PGI3, lipoxins, resolvins, protectins, maresins, nitrolipids and endothelial nitric oxide are expected to prevent, halt or even reverse the
low-grade systemic inflammation and help in the prevention and management of insulin resistance, type 2 diabetes mellitus, the metabolic
syndrome, hypertension, atherosclerosis and IHD as shown in the figure. Green arrows indicate enhancement in the formation of PGE1, PGI2,
PGI3, lipoxins, resolvins, protectins, maresins, nitrolipids and endothelial nitric oxide and prevention, halt and/or reversal of low-grade systemic
inflammation, insulin resistance, type 2 diabetes mellitus, the metabolic syndrome, hypertension, atherosclerosis and IHD. Red arrows indicate
how a defect in the activity of enzymes Δ
6 and Δ
5 desaturases could lead to a decrease in the formation of PGE1, PGI2, PGI3, lipoxins, resolvins,
protectins, maresins, nitrolipids and endothelial nitric oxide and initiation and progression of low-grade systemic inflammation, insulin resistance,
type 2 diabetes mellitus, the metabolic syndrome, hypertension, atherosclerosis and IHD.
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Page 7 of 10significant side effects. It is also proposed that a defect
in the activities of enzymes Δ
6 and Δ
5 and desaturases
and consequent low plasma and tissue levels of GLA,
DGLA, AA, EPA and DHA and their products lipoxins,
resolvins, resolvins, protectins, maresins and nitrolipids
may play a significant role in the development of insulin
resistance, atherosclerosis, the metabolic syndrome and
IHD in Europeans and other populations.
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